English Deutsch 中文
XinTech
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
XinTech
Menu Deutsch 中文

HMP’s Positive fruquintinib POC Study Triggers Payments from Lilly

May. 13, 2015

Hutchison Medipharma announced on May 13, 2015 that it is set to receive a total of US$18 million in payments from Eli Lilly and Company (Lilly).  The payments have been triggered by the positive results of the first proof-of-concept (POC) study for fruquintinib in the treatment of patients with metastatic colorectal cancer (mCRC) in China.  Fruquintinib, a novel selective inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinases, was discovered by HMP.